Downtrend on the daily chart: below its 50- and 200-day averages · 50-day below the 200-day · SuperTrend down since Sep 2 · below the Ichimoku cloud · RSI 41 · MACD above its signal · 6% above its 52-week low
None of the 29 investors followed here reported a position in 2192.HK in their latest filing.
From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors
No member of Congress has disclosed a 2192.HK trade since 2025.
From House and Senate STOCK Act reports. Members disclose trades, not holdings, as value ranges up to 45 days later, so amounts are estimates and “last move” is a hint at who still holds it, not a position. All recent congress trades
| Date | Insider | Transaction | Shares | Value |
|---|---|---|---|---|
| Apr 1, 2026 | Tian (Liping)Chief Executive Officer | — | 700K | — |
| Mar 31, 2026 | Tian (Lijun)Director (Executive) | — | 137.5K | — |
| Mar 31, 2026 | Tian (Lixin)President | — | 137.5K | — |
| Mar 1, 2026 | Tian (Liping)Chief Executive Officer | — | 300K | — |
| Feb 24, 2026 | Tian (Lixin)President | — | 200K | — |
| Dec 30, 2025 | Tian (Lijun)Director (Executive) | — | 200K | — |
| Dec 30, 2025 | Tian (Liping)Chief Executive Officer | — | 500K | — |
| Dec 8, 2025 | Tian (Lijun)Director (Executive) | — | 300K | — |
| Dec 8, 2025 | Tian (Liping)Chief Executive Officer | — | 500K | — |
| Dec 8, 2025 | Tian (Lixin)President | — | 300K | — |
| Oct 12, 2025 | Tian (Liping)Chief Executive Officer | — | 534.5K | — |
| Jul 17, 2025 | Tian (Lijun)Director (Executive) | Sale at price 1.91 per share. | 240K | $459.50K |
| Jul 16, 2025 | Tian (Lijun)Director (Executive) | Sale at price 1.92 per share. | 211K | $405.48K |
| Jul 15, 2025 | Tian (Lijun)Director (Executive) | Sale at price 1.90 per share. | 449K | $850.94K |
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Year |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.5 | -12.0 | -5.7 | 1.9 | -14.0 | -8.3 | 14.5 | -1.9 | -11.9 | -2.4 | −32.8% | ||
| 2025 | -12.6 | 40.6 | 7.4 | -7.6 | 3.8 | 16.9 | 9.7 | -12.4 | -7.4 | -19.2 | -2.8 | -4.6 | −1.5% |
| 2024 | -27.1 | 20.2 | 1.6 | 10.3 | -8.8 | -1.8 | 0.8 | 7.6 | 14.2 | -8.5 | 16.0 | 1.3 | +17.1% |
| 2023 | 26.8 | -11.5 | 13.4 | -20.3 | -20.4 | 1.5 | -6.0 | 6.5 | 13.0 | -1.4 | 25.4 | -13.3 | −0.6% |
| 2022 | -53.0 | -10.0 | -31.5 | 17.7 | -3.9 | 29.1 | -13.5 | 25.7 | -28.2 | -24.7 | 43.4 | -12.2 | −68.7% |
| 2021 | 7.3 | 14.4 | 7.4 | -1.9 | -31.4 | −11.1% |
Medlive Technology Co., Ltd. operates an online professional physician platform in Mainland China and internationally. The company's precision marketing and corporate solution provides digital marketing, digital detailing, digital marketing consultation, digital content creation, application software development, and other relevant services. Its medical knowledge solution offers medical education and clinical decision support, including licensing software to physicians and other registered users, such as other healthcare professionals and pharmaceutical companies. The company's intelligent patient management solutions include single disease management services, such as disease knowledge dissemination and treatment compliance monitoring; patient education services comprising content development, application software development, and other related services; and chronic disease management services for breast cancer, lung cancer, ovarian cancer, Parkinson's, lymphoma, stroke, and diabetes management. In addition, it is involved in the provision of research and development services; provision of internet hospital services; provision of publication and planning services for medicine guidelines and medical consensus; organizing medical exhibition conferences; provision of medical services; and provision of research services to pharmaceutical companies. The company was formerly known as Kingyee Co., Limited and changed its name to Medlive Technology Co., Ltd. in February 2021. The company was founded in 1996 and is headquartered in Beijing, China.
Buy / hold / sell counts
No recent headlines.